Our top findings are below, and detailed in the corresponding report, Life After GLP-1s We commissioned this survey to better understand the real-world experience of people after stopping GLP-1s, a perspective thats largely missing from the national conversation, said Catherine Metzgar, PhD, RD, and health coach at Virta
Contraindications: As noted, history of MTC or MEN2 is a contraindication
Limited exceptions: Case-by-case PA review for certain FDA-approved non-weight-loss uses (e.g., Wegovy for CVD risk reduction or MASH , Zepbound for OSA ) and EPSDT for members under 21
Appraising the role of astrocytes as suppliers of neuronal glutathione precursors
Supports gut health Regulates blood sugar Promotes satiety (feeling full) Lowers risk of chronic diseases Yet, despite these benefits, most people dont get enough the "fiber gap" is real
Studies indicate that any reduction in metabolic rate during GLP-1 treatment is primarily attributable to: Decreased body mass : A smaller body naturally requires less energy for basic physiological functions Loss of metabolically active tissue : Both fat and lean tissue contribute to resting energy expenditure Normal adaptive thermogenesis : The body's natural response to caloric restriction and weight loss Comparative studies examining GLP-1-induced weight loss versus equivalent weight loss through diet and exercise show similar metabolic adaptations, suggesting the medications do not cause additional metabolic suppression beyond what would be expected with weight loss by any means